Main Uses of Vaxchora

Vaxchora is an oral vaccine used to help prevent cholera, an acute diarrheal infection caused by the ingestion of food or water contaminated with the bacterium Vibrio cholerae. It is specifically indicated for individuals traveling from non-endemic areas to parts of the world where cholera is known to be present.

Targeting Serogroup O1

The vaccine is designed to protect against the O1 serogroup, which is the primary cause of cholera outbreaks globally. By introducing a weakened, live version of the bacterium, the vaccine helps the immune system recognize and respond to the pathogen more effectively upon exposure.

Benefits and Efficacy

The primary benefit of this vaccine is the reduction in the risk of developing severe diarrhea and dehydration, which are the hallmark symptoms of cholera.

Rapid Protection

Clinical studies have shown that the vaccine can provide protection relatively quickly after administration. It is often utilized by travelers who may have limited time before their departure to an area with active cholera transmission.

Reduction of Disease Severity

Beyond preventing infection, the vaccine is intended to reduce the intensity of symptoms if a person is exposed to the bacteria. In travelers, this helps mitigate the risk of life-threatening fluid loss and the need for emergency medical intervention in regions where healthcare resources may be limited.

Vaxchora is indicated for active immunization against cholera in persons 2 through 64 years of age who are traveling to cholera-affected areas.

Populations Who Must Not Use Vaxchora

Use of this vaccine is absolutely contraindicated in several groups. This includes individuals with a documented history of a severe allergic reaction to any vaccine component or to a previous dose of any cholera vaccine. Due to the live attenuated nature of the product, Vaxchora is also contraindicated in individuals with a congenital immune deficiency or those currently undergoing immunosuppressive treatment. Furthermore, individuals who have received oral or parenteral antibiotics within 14 days before vaccination must not be administered Vaxchora, as these medications can interfere with the live vaccine strain.

Age and Conditional Restrictions

The safety and effectiveness of the vaccine have not been established in children younger than 2 years of age or in adults 65 years of age and older. Vaccination should be postponed if the recipient has an acute moderate or severe illness (e.g., fever, diarrhea). Use is also generally not recommended during pregnancy or breastfeeding, as definitive safety data is limited and the vaccine is a live product.

Interactions with other medicines and products

The interaction profile for Vaxchora, a live attenuated oral vaccine, is defined by constraints necessary to ensure the survival and multiplication of the active strain, thus generating a sufficient protective immune response. These officially documented interactions are primarily classified as pharmacodynamic or administration-timing restrictions.

Medicinal Products and Treatments

• Systemic Antibiotics: Co-administration with oral or parenteral systemic antibiotics must be avoided. Regulatory documentation requires that Vaxchora not be administered to patients who have received antibiotics within 14 days prior to vaccination. This restriction is mandated because antibiotics may prevent the live strain from multiplying sufficiently, resulting in a diminished protective immune response.

• Immunosuppressive Treatments: Treatments that suppress the immune system, including irradiation, cytotoxic drugs, and corticosteroids used at greater than physiologic doses, may reduce the immune response to Vaxchora.

• Antimalarial Agents: Vaxchora must be administered at least 10 days before beginning antimalarial prophylaxis with Chloroquine, as co-administration may diminish the resulting immune protection.

• Other Live Oral Vaccines: An interval of 2 hours between the administration of Vaxchora and the Oral Typhoid Vaccine (Ty21a) is required to avoid physical interference with the enteric-coated capsule.

Food and Substance Constraints

• Food and Drink: Official regulatory documentation requires the recipient to avoid eating or drinking for 60 minutes before and 60 minutes after ingesting Vaxchora to ensure proper vaccine efficacy.

• Sweeteners: The addition of any sweeteners or medicinal flavorings, apart from a small, specified amount of sucrose or non-flavored stevia, is prohibited during preparation, as this is documented to reduce vaccine effectiveness.

Intestinal Colonization and Replication

Vaxchora is a modified, live-attenuated Vibrio cholerae O1 classical Inaba strain CVD 103-HgR. The strain acts within the gastrointestinal system to provide localized presentation of bacterial surface antigens. Upon ingestion, this non-pathogenic strain transiently colonizes and replicates in the small intestine. This initial molecular step is crucial, as it provides a localized presence of key bacterial components within the primary site of infection.

---

Induction of Vibriocidal Antibody Response

The colonization initiates signaling sequences within the adaptive immune system. Specifically, the strain stimulates the body to produce serum vibriocidal antibodies—proteins that bind to and target the V. cholerae bacteria. This process also induces the formation of memory B cells. This cascade leads to the establishment of a systemic and mucosal serum vibriocidal antibody response, constituting the main physiological adjustment driven by the vaccine strain.

Administration of Vaxchora

Vaxchora is administered as a single oral dose for active immunization against Vibrio cholerae serogroup O1. The vaccine is a suspension reconstituted from two separate packets: a buffer component (Packet 1) and an active component (Packet 2).

---

Dosing and Scheduling

The full dose must be ingested a minimum of 10 days before the start of travel or potential exposure to cholera. The standard volume of the oral suspension is 100 mL for persons aged 6 through 64 years. For children 2 through 5 years of age, the required volume is 50 mL. The safety and effectiveness of revaccination have not been established.

---

Preparation and Intake Requirements

To maintain the viability of the live attenuated vaccine, the suspension must be prepared using 100 mL of cold or room temperature bottled water (purified, spring, or sparkling); tap water is not permitted. The buffer packet (Packet 1) must be dissolved first, before the contents of the active component packet (Packet 2) are added. Recipients must avoid eating and drinking for 60 minutes before and after consumption to prevent interference with the buffer's function. The final suspension must be consumed promptly, typically within four hours of reconstitution if no sweetener is added.

---

Procedural Constraints

Due to the biological nature of the vaccine, administration requires specific timing relative to other agents. The vaccine should not be given to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination. Additionally, Vaxchora should be administered at least 10 days before beginning antimalarial prophylaxis with chloroquine to mitigate any potential reduction in immune response. If less than half of the prescribed dose volume is consumed, a full dose may be repeated within 72 hours.

Research Evidence / Overview of Studies for Vaxchora

The research base for Vaxchora focuses primarily on its ability to stimulate the immune system and was evaluated for its short-term protective capacity against the specific strain of cholera it targets. The findings that informed the regulatory evaluation were primarily derived from specialized, controlled clinical trials that examine the immediate effects of the vaccine.

---

Evidence for Active Immunization Against Cholera

Research exploring the protective capacity of Vaxchora was primarily based on a specific kind of rigorous study called a Randomized, Double-Blind, Placebo-Controlled Human Challenge Trial. This type of study involved healthy adult volunteers who were assigned either the vaccine or an inactive substance (placebo). Researchers monitored the participants who were exposed to the Vibrio cholerae O1 bacteria as part of the controlled study protocol.

These studies were used in research examining how symptoms change over time and what outcomes were related to physical discomfort. The clinical endpoints studied were outcomes reflecting daily functioning or activity level, specifically moderate to severe diarrhea measured by the total volume of diarrheal stool. The findings describe patterns observed in the studies regarding how the vaccine was associated with the incidence of this acute physical manifestation of the illness within a defined short period after exposure.

Study Landscape and Primary Measures of Protection

Beyond clinical endpoints, studies also monitored a key biological outcome called the Serum Vibriocidal Antibody (SVA) response. Research explored how this specific type of antibody response evolved in the observed populations following vaccination. Seroconversion—which means the body reached a certain measured level of these antibodies—is considered a surrogate endpoint, or a secondary marker used as a correlate of protection for regulatory purposes.

Key Limitations and Areas of Uncertainty

Research provides insight into short-term changes, but several important research limitations exist in the current evidence landscape. Long-term effects are not fully established; the precise duration of clinical protection following vaccination remains unknown beyond the 3-month efficacy assessment period reported in the human challenge studies. The effectiveness of Vaxchora has not been studied in persons aged 65 years and older, and is not established for individuals who already reside in or frequently travel to cholera-endemic areas.

Key Studies & References

1. Vaxchora™ Clinical Data Summary

Common questions about Vaxchora (FAQ)

Q: Does Vaxchora protect against all causes of traveler's diarrhea?

Vaxchora is officially indicated for active immunization against disease caused by Vibrio cholerae serogroup O1. Official product information indicates that the vaccine's effectiveness has not been established against other non-O1 serogroups of Vibrio cholerae or other bacteria that commonly cause traveler's diarrhea.

Q: How long does the protection from Vaxchora last?

Studies examined the vaccine’s efficacy at 10 days and up to 3 months following vaccination. Beyond the 3-month efficacy assessment period reported in clinical studies, the precise duration of protection is unknown. Additionally, the safety and effectiveness of taking the vaccine again (revaccination) have not been established in regulatory documents.

Q: How quickly after taking Vaxchora does it start to work?

Official guidelines require the dose to be taken a minimum of 10 days before travel or potential exposure. This period allows time for the live attenuated bacteria to replicate in the gastrointestinal tract and adequately induce the required immune response (antibody development) associated with protection.

Q: Do children experience different side effects from Vaxchora than adults?

The most commonly reported adverse reactions in clinical studies were generally similar across adult and pediatric age groups. However, the frequency (incidence) of some reactions varied between children and adults. For example, headache, tiredness, abdominal pain, and loss of appetite are listed among the most common adverse reactions for children and adolescents.

Q: Can people with certain chronic gastrointestinal issues use Vaxchora?

Regulatory documents indicate that the effects of vaccination and the degree of protection in individuals with chronic gastrointestinal disease are unknown. Official guidance states that vaccination is typically postponed in individuals with an acute moderate or severe illness, such as a fever or diarrhea, until after recovery.

Q: Where can I find the official prescribing information for Vaxchora?

The official regulatory documents, such as the U.S. FDA Prescribing Information (Label) or the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC), contain the complete and authoritative details about the vaccine. These comprehensive documents are typically available on the respective government health or drug agency websites.

Q: Which regulatory agencies have approved Vaxchora for use?

The vaccine has been approved for use by major global regulatory bodies. These include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), among others.

Q: What does 'live, attenuated' mean regarding Vaxchora?

Vaxchora is classified as a live, attenuated vaccine. This means it contains a weakened (attenuated) version of the Vibrio cholerae bacteria which can temporarily replicate in the intestines to stimulate an immune response, but it has been modified to prevent it from causing severe cholera disease.

Q: If Vaxchora is vomited up shortly after taking it, is it still effective?

Official documentation indicates that consuming less than half of the prescribed dose volume may result in diminished protective effects. If less than half the dose was consumed, guidance suggests that a full dose may be repeated within 72 hours.

Q: If I have already had cholera, do I still need Vaxchora?

The effectiveness of Vaxchora has not been established in people who have pre-existing immunity. This includes individuals who have had previous exposure to Vibrio cholerae or who have previously received a cholera vaccine.

Q: What is the consistency or taste of the Vaxchora liquid?

The reconstituted vaccine liquid is described as a slightly cloudy suspension that may contain some small white particles. To improve palatability (taste), official instructions permit the addition of a small, specified amount of table sugar or non-flavored stevia sweetener during preparation.

Q: Can Vaxchora be taken while on oral contraceptives?

Official regulatory documentation regarding drug interactions lists systemic antibiotics, antimalarial agents like chloroquine, and immunosuppressive treatments as requiring precautions or avoidance. Oral contraceptives are not listed among the documented interactions in the official product information.

Q: Does Vaxchora contain any known allergens like nuts or eggs?

The excipients (inactive ingredients) in the vaccine include lactose, sucrose, and hydrolyzed casein, which is a milk protein derivative. Official lists of ingredients do not include egg or peanut components. The official contraindication is a severe allergic reaction to any of its ingredients.

Q: What is the difference between a vaccine and a typical medicine, in the case of Vaxchora?

Vaxchora is officially described as a product for active immunization and prophylaxis (prevention). This means its primary function is to prepare the body's immune system to fight a future infection, rather than being used to treat an already active illness.

Q: Why is there a time limit for mixing and drinking Vaxchora?

Official instructions require prompt consumption to ensure the viability (survival) of the live attenuated vaccine strain. The regulatory time limit (e.g., within 4 hours if unsweetened) is mandated to preserve the characteristics of the vaccine needed to successfully stimulate an immune response.

Q: What is the general success rate of Vaxchora in studies?

Research from human challenge trials indicated that Vaxchora was associated with a 90.3% protective efficacy against moderate to severe diarrhea 10 days after vaccination. This protective efficacy was observed to be 79.5% at 3 months after vaccination in the studied populations.

The official regulatory requirements dictate specific conditions for storing and handling Vaxchora to maintain its stability.

Storage Requirements

• Unopened Packets: The Buffer Component (Packet 1) and the Active Component (Packet 2) must be stored in the refrigerator between 2 C and 8 C (36 F and 46 F). They must be protected from light and moisture and kept in the original package until ready for use.
• Temporary Storage: The packets may be stored out of refrigeration at 9 C to 25 C for a maximum of five days prior to reconstitution, but not above 27 C.
• After Reconstitution: Once the vaccine is reconstituted with the appropriate bottled water, it must be consumed promptly. The liquid vaccine must be consumed within 4 hours if unsweetened, or within 30 minutes if mixed with table sugar or non-flavored stevia.

Disposal Instructions

All materials used in the preparation and administration of the vaccine, including the cup and any residue, must be treated as medical waste. Disposal must occur in a healthcare setting equipped to handle and dispose of medical waste in accordance with applicable local, state, and federal regulations.